The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform
Jonathan A. Ledermann - One of the best experts on this subject based on the ideXlab platform.
-
quality of life during olaparib Maintenance Therapy in platinum sensitive relapsed serous ovarian cancer
British Journal of Cancer, 2016Co-Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon J S Rustin, Clare L Scott, Werner Meier, Ronnie Shapirafrommer, Tamar SafraAbstract:Quality of life during olaparib Maintenance Therapy in platinum-sensitive relapsed serous ovarian cancer
-
Maintenance Therapy in ovarian cancer.
Current opinion in oncology, 2014Co-Authors: Saira Khalique, Jane Hook, Jonathan A. LedermannAbstract:Targeted therapies are being used as Maintenance Therapy to improve the outcome of ovarian cancer following standard treatment in the first-line setting and in recurrent disease. We review the different approaches being used, trial design, and the impact of Maintenance treatment on survival and quality of life. The greatest experience of Maintenance Therapy is with antiangiogenic agents. Several trials targeting vascular endothelial growth factor with bevacizumab or vascular endothelial growth factor receptor with oral tyrosine kinase inhibitors have demonstrated a prolongation in progression-free survival (PFS) following first or second-line treatment. Maintenance Therapy with olaparib, a poly ADP ribose polymerase inhibitor given post-platinum Therapy for recurrent disease, has led to a prolongation in PFS, particularly, in patients with a BRCA mutation. The results of immunoTherapy Maintenance studies, based on using cancer antigen 125 as an antigen, have been disappointing. A benefit in PFS often does not translate into overall survival improvement, largely because of crossover and postprogression therapies. This makes clinical interpretation of results more difficult. The principle of using molecular targeted Therapy to prolong the control of ovarian cancer has been clearly demonstrated. The greatest effect is on prolongation of PFS and, by adding to the effects of standard treatments, Maintenance Therapy is likely to help incrementally extend the 5-year survival of women with ovarian cancer.
K. G. Wormsley - One of the best experts on this subject based on the ideXlab platform.
-
Maintenance Therapy for peptic ulcer disease.
Alimentary Pharmacology & Therapeutics, 2007Co-Authors: K. G. WormsleyAbstract:SUMMARY Peptic ulcers tend to recur; recurrence may be associated with an increased risk of potentially lethal complications, such as haemorrhage or perforation. Therapy aims to keep ulcers in remission. Currently, the optimal Maintenance Therapy is long-term, continuous administration of antisecretory drugs. More than 80% of patients remain in remission during Maintenance Therapy. Maintenance Therapy may be required for the life of the patient, but it is acceptable to patients and is safe.
-
Maintenance Therapy in duodenal and gastric ulcer disease : survey of practice amongst British gastroenterologists
Alimentary pharmacology & therapeutics, 2007Co-Authors: E. J. S. Boyd, J. G. Penston, K. G. WormsleyAbstract:We have used a postal questionnaire to obtain data on the practice of Maintenance Therapy for peptic ulcer disease by members of the British Society of Gastroenterology. Completed questionnaires were returned by 434 members. Ninety-six per cent used Maintenance Therapy for patients with duodenal ulcer and 81% for gastric ulcer. Maintenance Therapy was considered to be safe (duodenal ulcer 91%; gastric ulcer 78%), acceptable to patients (duodenal ulcer gastric ulcer 89%; gastric ulcer 80%) and to reduce the incidence of ulcer complications (duodenal ulcer 81%; gastric ulcer 68%). There was consensus that increasing age of patient, current use of non-steroidal anti-inflammatory drugs, previous ulcer complications, and ulcer relapse after surgery were relatively strong indications for Maintenance Therapy. However, the proportion of patients who received Maintenance Therapy varied widely amongst respondents (from < 10% to > 50%). There was no agreement on the optimal duration of Therapy, nor on management of patients who relapsed during Maintenance Therapy. It appears that the criteria for use of Maintenance Therapy need to be better defined, and that established knowledge about the practice of Maintenance Therapy should be better disseminated and acted upon.
Thomas J. Herzog - One of the best experts on this subject based on the ideXlab platform.
-
A review of the current evidence for Maintenance Therapy in ovarian cancer
Gynecologic oncology, 2009Co-Authors: Talia Foster, T. Michelle Brown, Jane Chang, Hans D. Menssen, Marissa B. Blieden, Thomas J. HerzogAbstract:Abstract Objectives Ovarian cancer (OC) typically is diagnosed at advanced stages, in which the primary goal of Therapy is to prolong progression-free survival (PFS) and overall survival (OS). In recent years, Maintenance Therapy has been tested for this purpose in advanced OC (AOC). Literature on Maintenance Therapy in AOC was systematically reviewed to assess current knowledge regarding the impact of this therapeutic approach. Methods A MEDLINE search was performed 2/2009 for articles published 1/2001–1/2009 pertaining to OC Maintenance Therapy guidelines, patterns, and outcomes. A second search used keywords specific to Maintenance and included primary studies published in the last 10 years. Of 406 sources identified, 36 primary studies and 16 review articles were included in this systematic review. A third search used the keyword "consolidation" to find Maintenance articles not identified through other searches; of 48 additional sources, 13 primary studies and 6 reviews were included. A fourth search of non-MEDLINE-indexed sources yielded 14 additional relevant publications from the same time period. Results Among practice guidelines identified, only the National Comprehensive Cancer Network (NCCN) 2008 guidelines provide recommendations regarding Maintenance Therapy, assigning it a category 2B recommendation. No studies were identified that reported current treatment patterns or economic outcomes in Maintenance Therapy; quality of life data were reported in one study. A variety of agents have been tested for Maintenance, with paclitaxel the most commonly evaluated. The Southwest Oncology Group—Gynecologic Oncology Group 178 trial has found that 12 cycles of paclitaxel extend PFS (by 7 months) compared to 3 months paclitaxel, but could not adequately evaluate OS. Conclusions Maintenance Therapy may improve clinical outcomes in AOC, but additional research is needed to demonstrate an OS advantage. Future studies should investigate the long-term clinical benefit of Maintenance treatment and its impact on resource utilization and health-related quality of life.
-
The role of Maintenance Therapy and novel taxanes in ovarian cancer
Gynecologic oncology, 2006Co-Authors: Thomas J. Herzog, Robert L. Coleman, Maurie Markman, David Cella, J. Tate ThigpenAbstract:Despite several studies reporting various degrees of success, the role of Maintenance chemoTherapy in ovarian cancer remains controversial. This article reviews the available data and the controversy surrounding Maintenance Therapy. In addition, the role of novel taxanes, which may offer an improved therapeutic index and reduced toxicity relative to conventional therapies in this setting, is discussed. The available randomized clinical data on extended or Maintenance Therapy in ovarian cancer are reviewed. Available data indicate that patients with ovarian cancer undergoing taxane Maintenance chemoTherapy exhibit a reduced recurrence rate and a longer progression-free survival. While an additional randomized trial is needed to confirm these benefits and establish Maintenance Therapy as the standard of care, the authors conclude that Maintenance Therapy is a valuable option that should be discussed with patients until further data are available. The Gynecologic Oncology Group 212 trial is a randomized clinical trial that is designed to answer whether taxane Maintenance Therapy offers a survival advantage as well as to determine the impact of such a therapeutic regimen on a patient's quality of life. This trial is also designed to address some of the questions regarding the role of a novel taxane in Maintenance Therapy in ovarian cancer.
Dave Levitan - One of the best experts on this subject based on the ideXlab platform.
-
FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
2018Co-Authors: Dave LevitanAbstract:The FDA has granted approval of rucaparib for Maintenance Therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
-
FDA Grants Priority Review for Rucaparib as Ovarian Cancer Maintenance Therapy
2017Co-Authors: Dave LevitanAbstract:The FDA has granted priority review status to rucaparib as Maintenance Therapy for women with recurrent ovarian cancer, according to the drug’s developer.
-
Olaparib Now Approved as Maintenance Therapy, and in Tablet Form
2017Co-Authors: Dave LevitanAbstract:The FDA approved olaparib as Maintenance Therapy for adult patients with recurrent ovarian cancer. The agent is also now approved in tablet form.
J. Tate Thigpen - One of the best experts on this subject based on the ideXlab platform.
-
The role of Maintenance Therapy and novel taxanes in ovarian cancer
Gynecologic oncology, 2006Co-Authors: Thomas J. Herzog, Robert L. Coleman, Maurie Markman, David Cella, J. Tate ThigpenAbstract:Despite several studies reporting various degrees of success, the role of Maintenance chemoTherapy in ovarian cancer remains controversial. This article reviews the available data and the controversy surrounding Maintenance Therapy. In addition, the role of novel taxanes, which may offer an improved therapeutic index and reduced toxicity relative to conventional therapies in this setting, is discussed. The available randomized clinical data on extended or Maintenance Therapy in ovarian cancer are reviewed. Available data indicate that patients with ovarian cancer undergoing taxane Maintenance chemoTherapy exhibit a reduced recurrence rate and a longer progression-free survival. While an additional randomized trial is needed to confirm these benefits and establish Maintenance Therapy as the standard of care, the authors conclude that Maintenance Therapy is a valuable option that should be discussed with patients until further data are available. The Gynecologic Oncology Group 212 trial is a randomized clinical trial that is designed to answer whether taxane Maintenance Therapy offers a survival advantage as well as to determine the impact of such a therapeutic regimen on a patient's quality of life. This trial is also designed to address some of the questions regarding the role of a novel taxane in Maintenance Therapy in ovarian cancer.
